AR098959A1 - Síntesis de un compuesto antiviral e intermediarios de la misma - Google Patents
Síntesis de un compuesto antiviral e intermediarios de la mismaInfo
- Publication number
- AR098959A1 AR098959A1 ARP140104910A ARP140104910A AR098959A1 AR 098959 A1 AR098959 A1 AR 098959A1 AR P140104910 A ARP140104910 A AR P140104910A AR P140104910 A ARP140104910 A AR P140104910A AR 098959 A1 AR098959 A1 AR 098959A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- crystal
- salt
- give
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 56
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 51
- 150000003839 salts Chemical class 0.000 abstract 51
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000006239 protecting group Chemical group 0.000 abstract 6
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 4
- 150000001408 amides Chemical class 0.000 abstract 4
- 230000008878 coupling Effects 0.000 abstract 3
- 238000010168 coupling process Methods 0.000 abstract 3
- 238000005859 coupling reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 238000006254 arylation reaction Methods 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 238000010511 deprotection reaction Methods 0.000 abstract 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract 2
- 239000007822 coupling agent Substances 0.000 abstract 1
- 238000005686 cross metathesis reaction Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000010930 lactamization Methods 0.000 abstract 1
- 238000006798 ring closing metathesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C251/12—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Síntesis de un compuesto antiviral e intermediarios de la misma. Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (5) o un cocristal, o una sal del mismo; caracterizado porque comprende poner en contacto un compuesto de fórmula (3) o un cocristal, o una sal del mismo, con un compuesto de fórmula (4) bajo condiciones de O-arilación para dar el compuesto de fórmula (5) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo, PG es un grupo protector, y R¹ es un grupo saliente. Reivindicación 5: Un proceso para la preparación de un compuesto de fórmula (1) o un cocristal, o una sal farmacéuticamente aceptable del mismo, caracterizado porque comprende: a) poner en contacto un compuesto de fórmula (3) o un cocristal, o una sal del mismo, con un compuesto de fórmula (4) bajo condiciones de O-arilación para dar un compuesto de fórmula (5) o un cocristal, o una sal del mismo; b) someter el compuesto de fórmula (5) o un cocristal, o una sal del mismo a condiciones de N-desprotección para dar un compuesto de fórmula (6) o un cocristal, o una sal del mismo; c) poner en contacto el compuesto de fórmula (6) o un cocristal, o una sal del mismo con un compuesto de fórmula (7) o un cocristal, o una sal del mismo, bajo condiciones de acoplamiento de amida para dar un compuesto de fórmula (8) o un cocristal, o una sal del mismo; d) llevar a cabo la metátesis de cierre de anillo del compuesto de fórmula (8) o un cocristal, o una sal del mismo para dar un compuesto de fórmula (9) o un cocristal, o una sal del mismo; e) hidrogenar el compuesto de fórmula (9) o un cocristal, o una sal del mismo en presencia de un catalizador para dar un compuesto de fórmula (10) o un cocristal, o una sal del mismo; f) hidrolizar el compuesto de fórmula (10) o un cocristal, o una sal del mismo para dar un compuesto de fórmula (11) o un cocristal, o una sal del mismo; g) poner en contacto el compuesto de fórmula (11) o un cocristal, o una sal del mismo con un compuesto de fórmula (12) o un cocristal, o una sal del mismo; bajo condiciones de acoplamiento de amida para dar el compuesto fórmula (1) o un cocristal, o una sal farmacéuticamente aceptable del mismo, donde R es C₁₋₆ alquilo, PG es un grupo protector, y R¹ es un grupo saliente. Reivindicación 14: Un proceso para la preparación de un compuesto de fórmula (1) o un cocristal, o una sal farmacéuticamente aceptable del mismo, caracterizado porque comprende: a) poner en contacto un compuesto de fórmula (13) o un cocristal, o una sal del mismo, con un compuesto de fórmula (14) o un cocristal, o una sal del mismo, bajo condiciones de metátesis cruzada para dar un compuesto de fórmula (15) o un cocristal, o una sal del mismo, b) hidrogenar el compuesto de fórmula (15) o un cocristal, o una sal del mismo en presencia de un catalizador para dar un compuesto de fórmula (16) o un cocristal, o una sal del mismo; c) someter el compuesto de fórmula (16) o un cocristal, o una sal del mismo a condiciones de N-desprotección para dar un compuesto de fórmula (17) o un cocristal, o una sal del mismo; d) poner en contacto el compuesto de fórmula (17) con un agente de acoplamiento de amida bajo condiciones de lactamización para dar un compuesto de fórmula (10) o un cocristal, o una sal del mismo; e) hidrolizar el compuesto de fórmula (10) o un cocristal, o una sal del mismo para dar un compuesto de fórmula (11) o un cocristal, o una sal del mismo; y f) poner en contacto el compuesto de fórmula (11) o un cocristal, o una sal del mismo con un compuesto de fórmula (12) o un cocristal, o una sal del mismo bajo condiciones de acoplamiento de amida para dar el compuesto fórmula (1) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo y PG es un grupo protector. Reivindicación 16: Un compuesto caracterizado porque es de fórmula (4) o un cocristal, o una sal del mismo, donde R¹ es un grupo saliente. Reivindicación 17: Un compuesto caracterizado porque es de fórmula (5) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo y PG es un grupo protector. Reivindicación 18: Un compuesto caracterizado porque es de fórmula (6) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo. Reivindicación 19: Un compuesto caracterizado porque es de fórmula (7) o un cocristal, o una sal del mismo. Reivindicación 20: Un compuesto caracterizado porque es de fórmula (8) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo. Reivindicación 21: Un compuesto caracterizado porque es de fórmula (13) o un cocristal, o una sal del mismo. Reivindicación 22: Un compuesto caracterizado porque es de fórmula (14) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo. Reivindicación 23: Un compuesto caracterizado porque es de fórmula (15) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo y PG es un grupo protector. Reivindicación 24: Un compuesto caracterizado porque es de fórmula (16) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo y PG es un grupo protector. Reivindicación 25: Un compuesto caracterizado porque es de fórmula (17) o un cocristal, o una sal del mismo, donde R es C₁₋₆ alquilo. Reivindicación 26: Un compuesto caracterizado porque es de fórmula (18) o un cocristal, o una sal del mismo. Reivindicación 27: Un compuesto caracterizado porque es de fórmula (19) o un cocristal, o una sal del mismo. Reivindicación 28: Un compuesto caracterizado porque es de fórmula (4d) o un cocristal, o una sal del mismo. Reivindicación 29: Un compuesto caracterizado porque es de fórmula (2) o un cocristal, o una sal del mismo. Reivindicación 30: Un compuesto caracterizado porque es de fórmula (4a) o un cocristal, o una sal del mismo. Reivindicación 31: Un compuesto caracterizado porque es de fórmula (4b) o un cocristal, o una sal del mismo. Reivindicación 32: Un compuesto caracterizado porque es de fórmula (4c) o un cocristal, o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920446P | 2013-12-23 | 2013-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098959A1 true AR098959A1 (es) | 2016-06-22 |
Family
ID=52278856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104910A AR098959A1 (es) | 2013-12-23 | 2014-12-23 | Síntesis de un compuesto antiviral e intermediarios de la misma |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9440991B2 (es) |
| EP (1) | EP3087085B1 (es) |
| JP (1) | JP6425727B2 (es) |
| KR (1) | KR102366697B1 (es) |
| CN (3) | CN116813596A (es) |
| AR (1) | AR098959A1 (es) |
| AU (1) | AU2014370125B2 (es) |
| CA (1) | CA2934537C (es) |
| EA (1) | EA201691031A1 (es) |
| ES (1) | ES2724460T3 (es) |
| IL (1) | IL246064A0 (es) |
| MX (1) | MX2016008452A (es) |
| NZ (1) | NZ720745A (es) |
| PL (1) | PL3087085T3 (es) |
| PT (1) | PT3087085T (es) |
| SG (1) | SG11201604482QA (es) |
| SI (1) | SI3087085T1 (es) |
| TR (1) | TR201906413T4 (es) |
| TW (3) | TWI710547B (es) |
| WO (1) | WO2015100145A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
| KR20160036590A (ko) * | 2013-07-30 | 2016-04-04 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 제제 |
| MX2016008452A (es) | 2013-12-23 | 2016-10-14 | Gilead Sciences Inc | Sintesis de un tripeptido macrociclico inhibidor de ns3 de virus de la hepatitis c. |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9809576B1 (en) | 2014-07-18 | 2017-11-07 | Abbvie Inc. | Synthetic route to anti-viral agents |
| US9809534B1 (en) * | 2014-07-21 | 2017-11-07 | Abbvie Inc. | Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof |
| US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
| US10316338B1 (en) | 2015-01-30 | 2019-06-11 | Abb Vie Inc. | Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid |
| EP3315497B1 (en) | 2015-06-29 | 2020-01-08 | Central Glass Company, Limited | Method for producing fluorine-containing cyclopropane carboxylic acid compound |
| CN110461812A (zh) | 2017-02-01 | 2019-11-15 | 艾伯维公司 | 用于制备(±)-2-(二氟甲基)-1-(烷氧基羰基)-环丙烷甲酸和(±)-2-(乙烯基)-1-(烷氧基羰基)-环丙烷甲酸的酶促方法 |
| CN107739319A (zh) * | 2017-10-31 | 2018-02-27 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
| WO2019084740A1 (zh) * | 2017-10-31 | 2019-05-09 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
| CN107827748A (zh) * | 2017-11-14 | 2018-03-23 | 安徽华胜医药科技有限公司 | 一种乙酸2‑烯丙基环丙酯消旋体的合成方法 |
| KR102519417B1 (ko) | 2018-11-28 | 2023-04-10 | 삼성디스플레이 주식회사 | 스트레처블 표시 장치 |
| CA3130848A1 (en) | 2019-02-22 | 2020-08-27 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
| CN116041181A (zh) * | 2023-01-04 | 2023-05-02 | 广州巨元生化有限公司 | 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200605247B (en) * | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US8211891B2 (en) * | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
| UA100436C2 (en) * | 2008-07-22 | 2012-12-25 | Mepk Шарп Энд Доме Корп. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
| US8283310B2 (en) * | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2289880A1 (en) * | 2009-07-08 | 2011-03-02 | Bayer CropScience AG | 2-Pyridinylcyclopropylbenzamide fungicides |
| EP2618665A4 (en) * | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | HCV NS3 proteinase inhibitor |
| NZ608720A (en) * | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| UY33775A (es) * | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2015095430A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Methods and intermediates for the preparation of macrolactams |
| MX2016008452A (es) | 2013-12-23 | 2016-10-14 | Gilead Sciences Inc | Sintesis de un tripeptido macrociclico inhibidor de ns3 de virus de la hepatitis c. |
| CA2934049A1 (en) | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
-
2014
- 2014-12-18 MX MX2016008452A patent/MX2016008452A/es unknown
- 2014-12-18 TR TR2019/06413T patent/TR201906413T4/tr unknown
- 2014-12-18 NZ NZ720745A patent/NZ720745A/en not_active IP Right Cessation
- 2014-12-18 US US14/576,143 patent/US9440991B2/en active Active
- 2014-12-18 CN CN202310617293.7A patent/CN116813596A/zh active Pending
- 2014-12-18 CA CA2934537A patent/CA2934537C/en active Active
- 2014-12-18 CN CN201480070017.2A patent/CN105849118B/zh active Active
- 2014-12-18 JP JP2016541595A patent/JP6425727B2/ja active Active
- 2014-12-18 EP EP14822040.3A patent/EP3087085B1/en active Active
- 2014-12-18 WO PCT/US2014/071319 patent/WO2015100145A1/en not_active Ceased
- 2014-12-18 CN CN202010152008.5A patent/CN111320610B/zh active Active
- 2014-12-18 SG SG11201604482QA patent/SG11201604482QA/en unknown
- 2014-12-18 PL PL14822040T patent/PL3087085T3/pl unknown
- 2014-12-18 KR KR1020167016776A patent/KR102366697B1/ko active Active
- 2014-12-18 EA EA201691031A patent/EA201691031A1/ru unknown
- 2014-12-18 ES ES14822040T patent/ES2724460T3/es active Active
- 2014-12-18 SI SI201431166T patent/SI3087085T1/sl unknown
- 2014-12-18 AU AU2014370125A patent/AU2014370125B2/en active Active
- 2014-12-18 PT PT14822040T patent/PT3087085T/pt unknown
- 2014-12-22 TW TW108125271A patent/TWI710547B/zh active
- 2014-12-22 TW TW103144804A patent/TWI671292B/zh active
- 2014-12-22 TW TW109137288A patent/TWI762003B/zh active
- 2014-12-23 AR ARP140104910A patent/AR098959A1/es unknown
-
2016
- 2016-06-06 IL IL246064A patent/IL246064A0/en unknown
- 2016-08-03 US US15/227,527 patent/US10030033B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098959A1 (es) | Síntesis de un compuesto antiviral e intermediarios de la misma | |
| AR131188A2 (es) | Proceso para producir derivado de diazabiciclooctano y su intermediario | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| PE20150944A1 (es) | COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa)) | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| MX373196B (es) | Inhibidores de histona desacetilasa novedosos. | |
| PT3638696T (pt) | Uso do anticorpo anti-cd70 argx-110 para tratar leucemia mielóide aguda | |
| AR096238A1 (es) | Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| EA201200728A1 (ru) | Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат | |
| AU2016238551B2 (en) | Bifunctional cytotoxic agents containing the CTI pharmacophore | |
| EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
| BR112015002275A2 (pt) | processos e intermediários para a preparação de inibidores da integrase | |
| AR088763A1 (es) | Proceso para producir un producto acrilato | |
| MX2021014844A (es) | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. | |
| BR112015024859A2 (pt) | processo e intermediários para a preparação de pregabalina | |
| MX2015015483A (es) | Composicion de tratamiento para cabello. | |
| MY187802A (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| MX355222B (es) | Proceso industrial para la sintesis de acetato de ulipristal y su analogo 4'-acetil. | |
| ES2723437T3 (es) | Procesos y productos intermedios para la preparación de un inhibidor de PDE10 | |
| MX384260B (es) | Proceso para la preparacion de 3,7-dimetilnonan-1-ol. | |
| EA202090788A1 (ru) | Жидкая композиция для использования в качестве противовоспалительного средства | |
| MX345278B (es) | Procedimiento de sintesis del 3,4-dimetoxibiciclo[4.2.0]octa-1,3,5 -trien-7-carbonitrilo, y aplicacion a la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |